[Federal Register Volume 85, Number 67 (Tuesday, April 7, 2020)]
[Notices]
[Page 19491]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-07262]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2020-N-0626]


Pulmonary-Allergy Drugs Advisory Committee; Postponed

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The meeting of the Pulmonary-Allergy Drugs Advisory Committee 
(PADAC) scheduled for April 21, 2020, is postponed. The Food and Drug 
Administration (FDA), like other government agencies, is taking the 
necessary steps to ensure the Agency is prepared to continue our vital 
public health mission in the event that our day-to-day operations are 
impacted by the COVID-19 public health emergency. Therefore, we are 
canceling or postponing all non-essential meetings through the month of 
April. We will reassess on an ongoing basis for future months. 
Therefore, this meeting is being postponed. The meeting was announced 
in the Federal Register on February 20, 2020.

FOR FURTHER INFORMATION CONTACT: LaToya Bonner, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-
796-9001, Fax: 301-847-8533, email: PADAC@fda.hhs.gov, or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area), and follow the prompts to the desired center or 
product area. Please call the Information Line for up-to-date 
information on this meeting, which was announced in the Federal 
Register of February 20, 2020 (85 FR 9780).

    Dated: April 1, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-07262 Filed 4-6-20; 8:45 am]
BILLING CODE 4164-01-P


